E2F2 and neoplasm: Disruption of E2F2/NBR1/MHC‐I signaling by shRNA or blockade of the corresponding antibodies largely abolished the tumor‐supportive effects of LINC01232 and inhibited tumor growth driven by M2‐type macrophages.